Fujitsu Honored by the International Headache Society
TOKYO, Mar 2, 2022 – (JCN Newswire via SEAPRWire.com) – Fujitsu today announced that it was the first company in the world to be honored by the Global Patient Advocacy […]
Societal cost of 6 common mental health disorders estimated at $1.7b yearly: IMH study
SINGAPORE – A study by the Institute of Mental Health (IMH) has identified for the first time the societal cost of six common mental health disorders here, estimated at about […]
Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong
TOKYO, Jul 1, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and […]
DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders
TOKYO, Mar 17, 2021 – (JCN Newswire via SEAPRWire.com) – Deutsches Zentrum fur Neurodegenerative Erkrankungen and Eisai Co., Ltd. today announced that both parties have entered into a research collaboration […]
New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong
TOKYO, Mar 2, 2021 – (JCN Newswire) – Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed […]